Huadong Medicine’s Semaglutide Injection Accepted for Review by China’s NMPA
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...
Shanghai has finalized its list of second-tier backup suppliers and manufacturers for specialized drug formulations...
Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing...
The national Volume-Based Procurement (VBP) authorities have released comprehensive details regarding the 10th VBP round,...
The preliminary outcomes of the 10th round of China’s national volume-based procurement (VBP) program were...
Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its combination drug QL1706, comprising iparomlimab...
Alibaba Health Information Technology Ltd (HKG: 0241), the health industry arm of Chinese e-commerce giant...
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has presented updated results from the...
Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its biosimilar version of Novartis’s blockbuster...
Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...
Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO:...
Johnson & Johnson (J&J, NYSE: JNJ)’s pulmonary hypertension treatment, Opsumit (macitentan), is set to encounter...
The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic version...
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has received approval from the National...
The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic bendamustine,...
The National Medical Products Administration (NMPA) in China has granted marketing approval to Qilu Pharmaceutical...
The medical ethics professional committee of the China Anti-Cancer Association (CACA) has announced the formation...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a Chinese pharmaceutical company, has announced that it...
The National Medical Products Administration (NMPA) website has indicated that Qilu Pharmaceutical’s Category 1 drug,...
Suzhou Ribo Life Science Co., Ltd, a specialist in small interfering RNA (siRNA) drugs based...